# AHK-Cu Peptide

> AHK-Cu is a copper-binding Ala-His-Lys tripeptide that acts on hair-follicle elongation, dermal papilla cells, and scalp-support pathways.

Canonical: https://pepflow.app/peptides/ahk-cu/

The Follicle Signal

A copper-binding Ala-His-Lys tripeptide best known for hair-follicle laboratory research, where AHK-Cu stimulated isolated human follicle elongation and dermal papilla cell activity without establishing a controlled human scalp-treatment outcome.

Hair density  Scalp skin

Tier D

Evidence Limited

Safety Limited Data

FDA status Not Approved

Topical 503A Not Listed

Last reviewed August 11, 2026 13 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is AHK-Cu?

AHK-Cu is the copper complex of the tripeptide alanine-histidine-lysine. It sits in the same broad copper-peptide family as GHK-Cu, but the first amino acid differs: AHK begins with alanine, while GHK begins with glycine.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/29986520/>)

The direct AHK-Cu literature is much narrower than the GHK-Cu literature. Its anchor study used isolated human hair follicles and cultured dermal papilla cells, which makes it useful for hair-follicle biology but not enough to claim proven hair regrowth in people.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)

The biological reason people care is straightforward: dermal papilla cells help control the hair-growth cycle, and AHK-Cu is linked with follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers. In plain terms, it points to a follicle-support signal under laboratory conditions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

AHK-Cu should not be collapsed with GHK-Cu or Pal-AHK. GHK-Cu is the better-studied copper tripeptide for skin remodeling, while Pal-AHK is a palmitoylated derivative designed for topical delivery. Related structure does not make the evidence interchangeable.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## What AHK-Cu is investigated for

AHK-Cu evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Hair follicle elongation Topical 30% Limited

AHK-Cu has an ex vivo follicle-elongation signal, but proven topical hair regrowth in people has not been shown.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

No controlled human scalp outcome trial was identified for AHK-Cu. The available follicle-elongation evidence uses isolated human follicles outside the body, not topical use in people.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

#### Animal / mechanistic evidence

AHK-Cu stimulated elongation of human hair follicles ex vivo at laboratory concentrations.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### Dermal papilla cell proliferation Topical 30% Limited

Dermal papilla cell proliferation is a plausible hair-growth mechanism, but clinical hair-loss efficacy has not been established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

No finished-product human scalp trial was identified that shows AHK-Cu increases dermal papilla cell activity in vivo.[\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Animal / mechanistic evidence

Cultured dermal papilla cells showed proliferation with AHK-Cu; this follicle-cell population is involved in hair-cycle signaling.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### Hair-follicle cell survival signaling Topical 28% Limited

Hair-follicle cell-survival signaling is plausible follicle support, but anti-shedding or hair-restoration outcomes remain unproven.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

No controlled human outcome source shows that AHK-Cu reduces follicle-cell apoptosis on the scalp.[\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

#### Animal / mechanistic evidence

AHK-Cu shifted anti-apoptotic markers in dermal papilla cells, including a higher Bcl-2/Bax ratio and lower cleaved caspase-3 and PARP measures.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### VEGF and TGF-beta skin signaling Topical 28% Limited

VEGF and TGF-beta changes are laboratory signals for skin and follicle biology; human skin-repair or anti-aging outcomes are not established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

No controlled human topical AHK-Cu clinical trial was identified for skin vascular signaling, wrinkle appearance, or wound outcomes.[\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

#### Animal / mechanistic evidence

Dermal fibroblast laboratory models showed proliferation, elevated VEGF production, and reduced TGF-beta1 secretion with AHK-Cu.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### Collagen type I support Topical 26% Limited

Collagen type I support has AHK-Cu laboratory evidence, but topical collagen remodeling in people has not been established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

#### Human evidence

No controlled human AHK-Cu topical skin-aging or collagen-density outcome trial was identified.[\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

#### Animal / mechanistic evidence

Dermal fibroblast laboratory models showed increased collagen type I production with AHK-Cu.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Evidence snapshot

### Overall confidence

Limited

42%

The AHK-Cu evidence base is narrow but concrete: one direct human-follicle laboratory paper plus broader copper-peptide and cosmetic-peptide literature. Human scalp outcomes remain unproven.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

### Human evidence

Insufficient

No controlled human scalp outcome trial was identified for AHK-Cu under the reviewed ingredient names.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

36%

### Animal / preclinical

Limited

Preclinical support is concentrated in one ex vivo and cell-culture human-follicle paper. It reported follicle elongation, dermal papilla proliferation, anti-apoptotic markers, VEGF and TGF-beta changes, and collagen type I production, but no finished-product scalp outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

38%

### Mechanism support

Limited

The lab signal includes follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers, which supports plausibility without proving clinical regrowth.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Forms & administration

AHK-Cu fits best as a topical/scalp cosmetic ingredient. Injection, mesotherapy, and drug-treatment claims should not be inferred from the current AHK-Cu evidence base.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

Topical

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Topical amounts follow the product label. Injectable protocols use about 250 mcg per dose.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Frequency

Topical and injectable protocols are usually once daily.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Timing Considerations

Topical use is usually in the evening. Injections are usually taken in the morning.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Cycle Length

Topical use is ongoing. Injectable cycles commonly run 4 weeks.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

[Full AHK-Cu dosage guide](<https://pepflow.app/peptides/ahk-cu/dosage/>)

## What to expect

### First 1-2 weeks

Scalp feel: calmer-feeling scalp, easy absorption, manageable residue, and a routine that fits daily use.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)

### Weeks 8-12

Subtle hair-cosmetic changes: steadier shedding patterns, slightly better hair feel, or a fuller-looking part line in consistent photos.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)

### Months 3-6

Gradual hair-cycle changes: reduced visible scalp, improved hair caliber, or more stable shedding patterns alongside the rest of the routine.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### After stopping

Scalp feel, shedding pattern, or visible density may gradually drift back toward baseline as the topical routine drops out, with hair-cycle changes moving slowly rather than day to day.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Safety profile

AHK-Cu safety is best handled as topical cosmetic safety plus evidence gaps. Monitor scalp irritation and product tolerability; do not infer injectable or disease-treatment safety from the current literature.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Common side effects

- Scalp redness [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- Itching or burning [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Cautions

- Open or inflamed scalp[\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- Injectable use[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

### What we don't know

Human scalp efficacy, topical pharmacokinetics, ideal concentration, long-term scalp safety, pregnancy safety, and interaction data remain unresolved.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

## Who AHK-Cu is not for

Route-specific avoid and medical-review notes:

- **Active scalp disease or open skin**

  Use medical review first for infection, open lesions, severe dermatitis, psoriasis flares, unexplained hair loss, or sudden shedding.[\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)
- **Pregnancy, breastfeeding, or pediatric use**

  Dedicated AHK-Cu safety data are not established for pregnancy, breastfeeding, or pediatric cosmetic use.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- **Known cosmetic ingredient sensitivity**

  People with previous reactions to peptide, copper-complex, preservative, fragrance, or solvent systems should treat new AHK-Cu products cautiously.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Other irritating scalp actives**

  Layering AHK-Cu with minoxidil vehicles, retinoids, acids, dyes, harsh shampoos, or microneedling can make irritation harder to interpret.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)
- **Additional copper peptides**

  Using several copper-peptide products at once can make irritation, staining, or tolerability attribution unclear; combination evidence is not established.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Regulatory status

### United States

United States: no FDA-approved AHK-Cu drug product was identified in the reviewed openFDA query. Topical cosmetic scalp products are regulated separately from drugs; hair-loss treatment claims can create drug claims.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Topical | Not Approved · openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) | Not Listed · The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval.[\[9\]](<https://www.fda.gov/media/94155/download>) |

### Topical

FDA drug approval

Not Approved

openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>) [\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

503A compounding

Not Listed

The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval.[\[9\]](<https://www.fda.gov/media/94155/download>)

### International

International status is market-, product-, and claim-specific. EU/Europe, the UK, Canada, and Australia regulate cosmetic products through cosmetic or industrial-chemical frameworks, while therapeutic hair-loss claims may trigger medicine or drug rules.[\[10\]](<https://eur-lex.europa.eu/eli/reg/2009/1223/oj/eng>) [\[11\]](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>) [\[12\]](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>) [\[13\]](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

### Sports & competition

Topical cosmetic AHK-Cu has no specific anti-doping issue identified in the reviewed materials. Systemic or injectable use is not athlete-cleared, and non-approved-substance logic can matter when a product is used as an unapproved drug.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>)

## How it works

The dermal papilla is a signaling hub at the base of the hair follicle. AHK-Cu is mechanistically interesting because its lab signal involves this follicle compartment rather than only generic skin fibroblasts.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

Follicle elongation and dermal papilla cell activity make AHK-Cu mechanistically plausible for scalp support. That is a lower-confidence statement than saying it treats hair loss.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

The copper-peptide family relationship helps explain why AHK-Cu gets compared with GHK-Cu, but GHK-Cu's skin-remodeling evidence should not be copied into AHK-Cu hair claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

## Research gaps & open questions

What the current literature has not yet settled about AHK-Cu:

01

Controlled scalp trials in people still need to show whether AHK-Cu meaningfully slows hair loss or improves hair growth.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

02

Finished-product studies should show whether topical formulas deliver enough AHK-Cu to the hair follicle to have an effect.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

03

Direct comparisons should test whether adding AHK-Cu improves results beyond established hair-loss treatments alone.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

04

AHK-Cu, GHK-Cu, and Pal-AHK need direct comparisons; results from one copper peptide should not be assumed to apply to the others.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Common questions

### Is AHK-Cu the same as GHK-Cu?

No. Both are copper tripeptides, but AHK-Cu has alanine in the first position and a much narrower hair-follicle evidence base, while GHK-Cu has broader skin-remodeling literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

### Is AHK-Cu clinically proven to regrow hair?

No. The direct evidence is an ex vivo and in vitro human hair-follicle study, not a controlled human scalp trial.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[6\]](<https://clinicaltrials.gov/search?term=AHK-Cu>)

### Is AHK-Cu topical or injectable?

AHK-Cu is best treated as a topical/scalp cosmetic ingredient. Injectable or mesotherapy use has no established clinical basis in the reviewed sources and should not be inferred from cosmetic products.[\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>)

### Can AHK-Cu replace minoxidil or prescription hair-loss treatment?

No. AHK-Cu is a preclinical follicle-support ingredient, not an evidence-based replacement for established medical hair-loss therapies.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>)

### Is AHK-Cu the same as Pal-AHK?

No. AHK-Cu is the copper complex, while Pal-AHK is a palmitoylated derivative discussed for cosmetic delivery. Their evidence should be reviewed separately.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Myths & misconceptions

### Myth

AHK-Cu is a clinically proven hair-loss treatment.

### Reality

Isolated follicles and cultured dermal papilla cells show meaningful follicle biology, but they are not a controlled human hair-loss trial.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Myth

AHK-Cu can use the same evidence score as GHK-Cu.

### Reality

The family relationship is real, but GHK-Cu's skin-remodeling evidence does not prove AHK-Cu scalp outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

### Myth

Injecting AHK-Cu into the scalp works better than topical use.

### Reality

Injectable AHK-Cu is not supported by the reviewed evidence and cosmetic products are not sterile injectable medicines.[\[7\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>)

## History & discovery

AHK-Cu entered the hair-peptide conversation through a 2007 laboratory study using isolated human hair follicles and dermal papilla cells, then spread into cosmetic scalp-product and copper-peptide discussions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)

Pyo and colleagues reported that AHK-Cu stimulated elongation of isolated human hair follicles and proliferation of cultured dermal papilla cells.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

Cosmetic and hair anti-aging reviews discussed peptides, copper tripeptides, and topical hair-support ingredients, while emphasizing the broader problem of limited randomized clinical evidence for many cosmetic peptides.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)

## Published research 13 citations

- [\[1\] **The effect of tripeptide-copper complex on human hair growth in vitro.** PubMed / Archives of Pharmacal Research, 2007-07. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)
- [\[2\] **GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.** PubMed / BioMed Research International, 2015. review.](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)
- [\[3\] **Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.** PubMed / International Journal of Molecular Sciences, 2018-07-07. review.](<https://pubmed.ncbi.nlm.nih.gov/29986520/>)
- [\[4\] **Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.** PubMed / Pharmaceuticals, 2021-07-21. review.](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- [\[5\] **Topical and nutricosmetic products for healthy hair and dermal antiaging using dual-acting plant-based peptides, hormones, and cannabinoids.** PubMed / FASEB BioAdvances, 2021-08. review.](<https://pubmed.ncbi.nlm.nih.gov/34377956/>)
- [\[6\] **ClinicalTrials.gov query for AHK-Cu and Copper Tripeptide-3** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/search?term=AHK-Cu>)
- [\[7\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration, 2025-11-20. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[8\] **openFDA Drugs@FDA query for AHK-Cu and Copper Tripeptide-3** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22AHK-Cu%22&limit=1>)
- [\[9\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[10\] **Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products** EUR-Lex. official guidance.](<https://eur-lex.europa.eu/eli/reg/2009/1223/oj/eng>)
- [\[11\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[12\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[13\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Matrikine/copper tripeptide

**Tier**

D

**Evidence**

42% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Topical 503A**

Not Listed

**Citations**

[13 citations](<https://pepflow.app/peptides/ahk-cu/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Hair follicle elongation
- Dermal papilla cell proliferation
- Hair-follicle cell survival signaling
- VEGF and TGF-beta skin signaling
- Collagen type I support

### Common side effects

- Scalp redness
- Itching or burning

### Also known as

- Copper tripeptide-3
- AHK copper peptide
- Ala-His-Lys copper

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [AHK-Cu dosage guide](<https://pepflow.app/peptides/ahk-cu/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
